Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.
Hillner
B E
BE
Kirkwood
J M
JM
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003362:Cost-Benefit Analysis; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use*; D008545:Melanoma / Q000191:economics / Q000628:therapy*; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins